Multiple sclerosis pill succeeds in key trial, Sanofi says - STAT News
Sanofi's tolebrutinib met its key goal in a Phase 3 MS study, potentially leading to regulatory approval, though not all patients saw benefits. The positive result boosts investor confidence in Sanofi's R&D capabilities.
Highlighted Terms
Related News
Multiple sclerosis pill succeeds in key trial, Sanofi says - STAT News
Sanofi's tolebrutinib met its key goal in a Phase 3 MS study, potentially leading to regulatory approval, though not all patients saw benefits. The positive result boosts investor confidence in Sanofi's R&D capabilities.